Summit Therapeutics plc Stock News

Illumina said on Tuesday Chief Financial Officer Joydeep Goswami would leave the gene sequencing company and would be succeeded by former Summit Therapeutics' executive Ankur Dhingra.

An analyst initiated coverage of Summit Therapeutics with an enthusiastic buy recommendation. He feels its investigational cancer drug has vast potential.

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Barclays 26th An

Summit Therapeutics Inc. (SMMT) Q4 2023 Earnings Call Transcript

MIAMI, Fla.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2

Summit Therapeutics Inc., backed by biotech billionaire Bob Duggan, has transitioned from developing antibiotics to becoming an oncology therapeutics developer. The company purchased the oncology asse

Summit's cash position is worrying. The company only has one therapy in clinical trials.

The company's current pipeline only includes two drugs. Summit Therapeutics' shares are up more than 93% over the past 12 months.

Strong Small-Cap Insider Buys: Q1 2023.

Summit Therapeutics is mostly owned by Bob Duggan, who made billions from selling Pharmacyclics. However, Pharmacyclics had something to sell.

Summit Therapeutics Inc. (NASDAQ:SMMT ) Q4 2022 Results Conference Call March 9, 2023 9:00 AM ET Company Participants Dave Gancarz - SVP, Corporate Strategy and Stakeholder Relations Dr. Maky Zanganeh

Summit Therapeutics rallied hard off 52-week lows in December after its licensing deal for Ivonescimab was announced. Gains have extended into the new year, which is promising for those seeking to ent

The fourth quarter of 2022 was relatively better for the stock markets, with the S&P 500 up over 7% (its only positive quarterly return for the year).

Small-cap stocks usually suffer more than mid- and large-cap stocks when the market as a whole is struggling, and when the market is rallying, they could offer higher returns as well.

The clinical-stage biopharma stock has been rising all year.